Evoke Pharma (EVOK) Competitors $5.21 -0.08 (-1.51%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.22 +0.00 (+0.10%) As of 09/5/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. THAR, DYAI, RNTX, MAAQ, RVPH, ITRM, CLSD, ASBP, CASI, and KZRShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Tharimmune (THAR), Dyadic International (DYAI), Rein Therapeutics (RNTX), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Iterum Therapeutics (ITRM), Clearside Biomedical (CLSD), Aspire Biopharma (ASBP), CASI Pharmaceuticals (CASI), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Its Competitors Tharimmune Dyadic International Rein Therapeutics Mana Capital Acquisition Reviva Pharmaceuticals Iterum Therapeutics Clearside Biomedical Aspire Biopharma CASI Pharmaceuticals Kezar Life Sciences Evoke Pharma (NASDAQ:EVOK) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Do institutionals and insiders believe in EVOK or THAR? 1.2% of Tharimmune shares are owned by institutional investors. 2.3% of Evoke Pharma shares are owned by company insiders. Comparatively, 10.0% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer EVOK or THAR? Tharimmune has a consensus price target of $17.00, indicating a potential upside of 361.96%. Given Tharimmune's stronger consensus rating and higher possible upside, analysts clearly believe Tharimmune is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evoke Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has preferable valuation & earnings, EVOK or THAR? Evoke Pharma has higher revenue and earnings than Tharimmune. Evoke Pharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$10.25M0.79-$5.35M-$2.56-2.04TharimmuneN/AN/A-$12.20M-$6.10-0.60 Is EVOK or THAR more profitable? Tharimmune has a net margin of 0.00% compared to Evoke Pharma's net margin of -42.07%. Evoke Pharma's return on equity of -99.48% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-42.07% -99.48% -33.58% Tharimmune N/A -1,239.20%-365.06% Does the media refer more to EVOK or THAR? In the previous week, Tharimmune had 3 more articles in the media than Evoke Pharma. MarketBeat recorded 4 mentions for Tharimmune and 1 mentions for Evoke Pharma. Tharimmune's average media sentiment score of 0.63 beat Evoke Pharma's score of 0.00 indicating that Tharimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evoke Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tharimmune 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, EVOK or THAR? Evoke Pharma has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. SummaryTharimmune beats Evoke Pharma on 11 of the 16 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.12M$4.35B$5.81B$9.91BDividend YieldN/A1.30%6.70%4.52%P/E Ratio-2.0410.1076.2926.13Price / Sales0.7916.95529.70172.90Price / CashN/A7.1636.9959.28Price / Book1.103.4611.486.09Net Income-$5.35M-$109.62M$3.29B$266.51M7 Day Performance-4.40%3.31%1.28%0.45%1 Month Performance-2.25%20.20%8.56%5.05%1 Year Performance34.63%40.73%61.19%26.03% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.0805 of 5 stars$5.21-1.5%N/A+34.6%$8.12M$10.25M-2.044Analyst UpgradeTHARTharimmune2.7914 of 5 stars$4.77-8.3%$17.00+256.4%+22.7%$33.86MN/A-0.782News CoverageShort Interest ↑Gap UpDYAIDyadic International3.0374 of 5 stars$0.98+2.9%$6.00+512.7%-27.8%$33.34M$3.49M-5.157Short Interest ↓Gap DownRNTXRein TherapeuticsN/A$1.26-6.7%N/AN/A$32.39MN/A-0.479Gap DownMAAQMana Capital AcquisitionN/A$3.89+2.1%N/A+1,189.5%$31.61MN/A0.001RVPHReviva Pharmaceuticals2.7399 of 5 stars$0.46+1.5%$5.20+1,030.4%-67.5%$30.60MN/A-0.715Gap UpITRMIterum Therapeutics2.8163 of 5 stars$0.63-1.7%$9.00+1,330.8%-37.2%$30.22MN/A-0.7410News CoveragePositive NewsShort Interest ↓CLSDClearside Biomedical2.2354 of 5 stars$0.34+0.3%$4.20+1,134.9%-64.3%$28.85M$1.66M-0.9230ASBPAspire BiopharmaN/A$0.59+1.8%N/AN/A$28.49MN/A0.00N/ACASICASI Pharmaceuticals3.7888 of 5 stars$2.33+1.3%$4.00+71.7%-64.0%$28.41M$28.54M-0.81180Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionKZRKezar Life Sciences2.6479 of 5 stars$3.89+1.6%$9.00+131.4%-27.3%$28.05MN/A-0.4060 Related Companies and Tools Related Companies THAR Alternatives DYAI Alternatives RNTX Alternatives MAAQ Alternatives RVPH Alternatives ITRM Alternatives CLSD Alternatives ASBP Alternatives CASI Alternatives KZR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
